Nyxoah is focused on the development and commercialization of innovative solutions and services to treat Obstructive Sleep Apnea (OSA). Nyxoah’s lead solution is the Genio® system, a CE-validated, patient-centered, bilateral hypoglossal nerve stimulation therapy for OSA, the world’s most common sleep disordered breathing condition which is associated with increased mortality risk and comorbidities including cardiovascular diseases, depression and stroke.

In Western countries alone there are over 1 million new eligible OSA patients each year who require treatment but have failed the current gold standard, Continuous Positive Airway Pressure (CPAP) therapy, which requires a bulky machine and wearing a mask at night. Neurostimulation is an effective and well-established therapy for OSA that can address this unmet need.